Molecular profile
Molecular profile
- Molecule class
- Peptide analogue
- Origin
- Synthetic analogue
- Primary target system
- GHRH-Rezeptor und pulsatile GH/IGF-1-Achse
- Development stage
- Authorised active substance
Stabilisiertes Analogon des humanen Wachstumshormon-Releasing-Hormons.
Mechanism and signalling
Mechanism and signalling
It activates pituitary GHRH receptors and thereby modulates the endogenous growth-hormone and IGF-1 axis.
Scientific classification
Scientific classification
This profile maps Tesamorelin to the research areas endocrine, metabolism. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Peptide hormones and analogues related to hypothalamic, pituitary and peripheral endocrine systems.
Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.
Evidence base
Approval and post-marketing data
Controlled trials and current prescribing information support the authorised U.S. use. The approval cannot be generalised to body-composition goals.
Regulatory status
Specifically approved in the U.S.
The substance has a specific U.S. approval. This does not constitute general authorisation in Germany or the European Union, nor approval of unlicensed products.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries